STI Stock Trade Intelligence
NEU

Neuren Pharmaceuticals Ltd

Health Care · ASX:NEU
$22.98
▼ -0.09%
Market cap
$2.92B
Turnover
$5,699,181
Last price
$22.98
Day change
-0.09%
Announcements
11
Range, past year
Open 18.89 · Low 10.91 · Now 22.98 · High 24.55
Open NEU in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

NEU momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-11-16.
Momentum quality
50/100
Wyckoff phase
Uptrend8d
Trend stage
Emerging
1 Day
-0.1%
1 Week
-3.6%
1 Month
+13.7%
1 Year
+20.9%
RSI
62
Avg daily range
4.0%

Neuren Pharmaceuticals Ltd scores 50 out of 100 for momentum quality, a reading rated low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Emerging.

On the Wyckoff cycle it sits in Uptrend, where it has been for 8 trading days. The weekly timeframe reads Uptrend, which agrees with the daily view.

Against the wider market it is currently outperforming and the institutional accumulation signal reads low.

What stands out
  • MACD histogram positive & rising
  • RSI in healthy zone (62)
Points to watch
Nothing flagged for NEU on this reading.
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

NEU announcements

Recent price-sensitive releases.
  • 2026-11-05 Q3 2026 DAYBUE net sales up 39%, full year guidance upgraded Profit Guidance | Progress Report
  • 2026-09-29 Trofinetide US patent protections extended to March 2041 Progress Report
  • 2026-09-29 Pause in Trading Notice Pending
  • 2026-08-26 Growing royalty anchors Neuren first ever dividend program Dividend Reinvestment Plan | Half Yearly Report | Dividend Record Date | Dividend Pay Date | Dividend Rate
  • 2026-08-26 Half Yearly Report and Accounts Half Yearly Report | Half Year Audit Review | Half Year Directors' Statement | Half Year Accounts | Half Year Directors' Report | Dividend Record Date | Dividend Pay Date | Dividend Rate
  • 2026-08-25 European Commission grants marketing authorisation for DAYBU Progress Report
  • 2026-08-05 Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded Progress Report
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.